Article on the outcome of Parkinson’s patients affected by COVID-19
A group of four Parkinson’s clinicians have published their findings of the outcomes of Parkinson’s disease in those affected by COVID-19, examining a cohort of 10 patients.
The article, 'Outcome of Parkinson’s Disease patients affected by COVID-19' by Prof Angelo Antonini, Dr Valentina Leta, Dr James Teo and Prof K Ray Chaudhuri, is the first during this coronavirus pandemic to assess the outcomes for those living with Parkinson’s who contract COVID-19.
The general commentary has been that Parkinson’s itself does not increase the risk of severity of COVID-19 for people, although associated factors like being older, and having associated respiratory problems make the disease more severe in those who do develop it.
However, this new report says that:
‘These findings suggest that PD patients of older age (mean 78.3 years) with longer disease duration (mean 12.7 years) are particularly susceptible to COVID-19 with a substantially high mortality rate (40%).
Those on advanced therapies, such as deep brain stimulation or levodopa infusion therapy, seem specially [sic] vulnerable and a mortality rate of 50% among our four such cases is of [sic] concern.’
The report goes on to conclude that:
‘Many national and charity guidelines do not list PD or specifically older subjects on advanced therapies as a susceptible group and this information needs to be amended in light of this new data.’
Parkinson’s Academy have updated their information accordingly.
'The things you can't get from the books'
Parkinson's Academy, our original and longest running Academy, houses 20 years of inspirational projects, resources, and evidence for improving outcomes for people with Parkinson's. Led by co-founder and educational director Dr Peter Fletcher, the Academy has a truly collegiate feel and prides itself on delivering 'the things you can't get from books' - a practical learning model which inspires all Neurology Academy courses.